Search results

Why do some jihadist organizations engage in beheadings while others do not? Although beheadings have become a signature tactic of the contemporary global jihadist movement, I show that most jihadist groups perpetrate few or no beheadings and only a minority have adopted beheading as a consistent part of their repertoire of violence. Such variation exists even among ideologically similar 'Salafi-jihadist' groups, suggesting that ideology alone cannot explain why such violence occurs. Instead, I argue that the use of beheadings is shaped by a combination of local strategic context and transnational ties. Beheadings are strategically useful to jihadist groups engaged in insurgency as a means of deterring civilian collaboration with the enemy, demoralizing enemy combatants and attracting foreign recruits. But the use of beheading is also costly for such groups, notably because of its tendency to alienate potential civilian supporters. Whether or not particular jihadist groups use beheadings depends largely on whether they can afford to ignore these costs. Jihadist insurgents who control significant territory are less sensitive to civilian attitudes because of their ability to obtain support through coercion and are therefore more likely to perpetrate beheadings. The use of beheadings is also shaped by transnational ties: organizations that seek formal affiliation with transnational jihadist networks are more likely to calculate that the benefits of using extreme violence to attract transnational support outweigh its costs. I test this theory using an original dataset of over 1,500 beheading events perpetrated by jihadist organizations between 1998 and 2019.

This paper reports the activity of different Ce-BEA zeolites for the catalytic oxidation of trichloroethylene and it is focused on determining the nature of the catalyst active sites. The study was made by using a microporous zeolite BEA, two types of desilicated BEA zeolites and mildly steamed desilicated BEA zeolites. The catalysts were prepared by introducing Ce to the zeolites with incipient wetness impregnation and their structural, textural, and acidic properties were established. The evolution of TCE conversion was correlated with the physicochemical properties of the zeolites. It is shown that highly developed mesopore surface area, well-dispersed cerium species and a high number of Brønsted sites results in the highest activity. The activity and selectivity of the Ce-loaded zeolites were found to be dependent on the number of high strength Brønsted acid centres. The hierarchical materials with a higher density of hydroxyls showed higher yields to HCl while the formation of chlorine was prevented. ; The work was financed by the Grant No. 2015/18/E/ST4/00191 from the National Science Centre, Poland. J.M-T. and A.E.P thank Spanish Governmentthrough "Severo Ochoa" SEV-2016-0683, RTI2018-099668-B-C21, RTI2018-101784-B-I00 and the Fundación Ramón Arecesthrough a research contract of the "Life and Materials Science" program.

Single, severe traumatic brain injury (TBI) which elevates CNS amyloid, increases the risk of Alzheimer's disease (AD); while repetitive concussive and subconcussive events as observed in athletes and military personnel, may increase the risk of chronic traumatic encephalopathy (CTE). We describe two clinical cases, one with a history of multiple concussions during a career in the National Football League (NFL) and the second with frontotemporal dementia and a single, severe TBI. Both patients presented with cognitive decline and underwent [18F]-Florbetapir positron emission tomography (PET) imaging for amyloid plaques; the retired NFL player also underwent [18F]-T807 PET imaging, a new ligand binding to tau, the main constituent of neurofibrillary tangles (NFT). Case 1, the former NFL player, was 71 years old when he presented with memory impairment and a clinical profile highly similar to AD. [18F]-Florbetapir PET imaging was negative, essentially excluding AD as a diagnosis. CTE was suspected clinically, and [18F]-T807 PET imaging revealed striatal and nigral [18F]-T807 retention consistent with the presence of tauopathy. Case 2 was a 56-year-old man with personality changes and cognitive decline who had sustained a fall complicated by a subdural hematoma. At 1 year post injury, [18F]-Florbetapir PET imaging was negative for an AD pattern of amyloid accumulation in this subject. Focal [18F]-Florbetapir retention was noted at the site of impact. In case 1, amyloid imaging provided improved diagnostic accuracy where standard clinical and laboratory criteria were inadequate. In that same case, tau imaging with [18F]-T807 revealed a subcortical tauopathy that we interpret as a novel form of CTE with a distribution of tauopathy that mimics, to some extent, that of progressive supranuclear palsy (PSP), despite a clinical presentation of amnesia without any movement disorder complaints or signs. A key distinguishing feature is that our patient presented with hippocampal involvement, which is more frequently seen in ...

Parkinson's disease is a complex heterogeneous disorder with urgent need for disease-modifying therapies. Progress in successful therapeutic approaches for PD will require an unprecedented level of collaboration. At a workshop hosted by Parkinson's UK and co-organized by Critical Path Institute's (C-Path) Coalition Against Major Diseases (CAMD) Consortiums, investigators from industry, academia, government and regulatory agencies agreed on the need for sharing of data to enable future success. Government agencies included EMA, FDA, NINDS/NIH and IMI (Innovative Medicines Initiative). Emerging discoveries in new biomarkers and genetic endophenotypes are contributing to our understanding of the underlying pathophysiology of PD. In parallel there is growing recognition that early intervention will be key for successful treatments aimed at disease modification. At present, there is a lack of a comprehensive understanding of disease progression and the many factors that contribute to disease progression heterogeneity. Novel therapeutic targets and trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination are required. The integration of robust clinical data sets is viewed as a powerful approach to hasten medical discovery and therapies, as is being realized across diverse disease conditions employing big data analytics for healthcare. The application of lessons learned from parallel efforts is critical to identify barriers and enable a viable path forward. A roadmap is presented for a regulatory, academic, industry and advocacy driven integrated initiative that aims to facilitate and streamline new drug trials and registrations in Parkinson's disease.